A certain blood test can successfully identify lymphangioleiomyomatosis (LAM) in some patients, eliminating the need for surgical lung biopsy to make a diagnosis, researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found.
These findings are being published in the July 6, 2010, edition of the journal Chest.
Congenital Cystic Adenomatoid Malformation Of The Lung
Congenital disease of the lung in which multiple cysts (water bubbles) develop in the lung tissues, sometimes affecting a whole lobe of the lungs.
Advertisement
LAM is a rare but serious lung disease that affects women, causing shortness of breath and lung collapse, called a pneumothorax. The disease occurs when an unusual type of cell invades the lungs and causes tissue destruction by creating holes or cysts in the lung. It can be fatal.
Lisa Young, MD, lead author on the study and researcher at UC and Cincinnati Children's, says that these findings will help with diagnosing LAM and may also be helpful in screening for LAM in women with Tuberous Sclerosis Complex (TSC), a genetic disorder that causes tumors to form in many different organs. TSC is a risk factor for the development of LAM.
![Pneumonia]( "Pneumonia")
Pneumonia is a lung infection that can be caused by a bacteria or a virus. It causes inflammation of the alveoli or the air sacs of the lungs.
In this study, the test was used to analyze the amount of a specific protein—vascular endothelial growth factor-D, or VEGF-D—in patients' blood. VEGF-D promotes the growth of lymphatic vessels and blood vessels and can be involved in the spread of cancer.
Researchers performed VEGF-D testing in 195 women and found that serum VEGF-D levels were significantly greater in women with LAM than in women with other lung diseases or healthy individuals. When they prospectively evaluated the VEGF-D test performance in women prior to knowing their diagnosis, the test showed high accuracy for diagnosis of LAM.
"We concluded that a serum VEGF-D level of greater than 800 pg/mL (picograms, or one-trillionth of a gram, per milliliter) in women with typical cystic changes on a high-resolution computed tomography (CT) scan is diagnostically specific for sporadic LAM and identifies LAM in women with TSC," Young says. "However, negative VEGF-D results do not exclude the diagnosis of LAM."
Frank McCormack, MD, senior author and director of pulmonary, critical care and sleep medicine at UC, says that Serum VEGF-D measurement is currently performed as part of a research protocol but will soon be available for clinical application.
"This was a team effort by clinicians around the world to collect blood samples and clinical data from patients with very rare lung diseases," he says. "Through their efforts and the generosity of patients who participated, we are optimistic that serum VEGF-D will join the ranks of diagnostic tests for lung disease, reduce the need for surgical lung biopsy and allow for intervention and trial recruitment earlier in the disease course."
Source: Eurekalert
Pneumonia
Pneumonia is a lung infection that can be caused by a bacteria or a virus. It causes inflammation of the alveoli or the air sacs of the lungs.
Advertisement
In this study, the test was used to analyze the amount of a specific protein—vascular endothelial growth factor-D, or VEGF-D—in patients' blood. VEGF-D promotes the growth of lymphatic vessels and blood vessels and can be involved in the spread of cancer.
Researchers performed VEGF-D testing in 195 women and found that serum VEGF-D levels were significantly greater in women with LAM than in women with other lung diseases or healthy individuals. When they prospectively evaluated the VEGF-D test performance in women prior to knowing their diagnosis, the test showed high accuracy for diagnosis of LAM.
"We concluded that a serum VEGF-D level of greater than 800 pg/mL (picograms, or one-trillionth of a gram, per milliliter) in women with typical cystic changes on a high-resolution computed tomography (CT) scan is diagnostically specific for sporadic LAM and identifies LAM in women with TSC," Young says. "However, negative VEGF-D results do not exclude the diagnosis of LAM."
Frank McCormack, MD, senior author and director of pulmonary, critical care and sleep medicine at UC, says that Serum VEGF-D measurement is currently performed as part of a research protocol but will soon be available for clinical application.
"This was a team effort by clinicians around the world to collect blood samples and clinical data from patients with very rare lung diseases," he says. "Through their efforts and the generosity of patients who participated, we are optimistic that serum VEGF-D will join the ranks of diagnostic tests for lung disease, reduce the need for surgical lung biopsy and allow for intervention and trial recruitment earlier in the disease course."
Source: Eurekalert
Respiratory Diseases
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like chronic obstructive pulmonary disease can lead to respiratory failure.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Decoding the eight factors affecting Black adults' life expectancy.
Sobering truth about foot travel in the United States emerges from international statistics, highlighting the prevalence of walking on the Blacksburg campus.
Unveiling a hidden mechanism, proteins within brain cells exhibit newfound abilities at synapses, reinforcing Darwin's theory of adaptation and diversity in the natural world.
Combining micro-needling and cupping, two emerging and alternative techniques, in an experimental study reveals a potential synergy for skin rejuvenation.
Despite a decline in COVID-19 cases, the World Health Organisation (WHO) raises global concerns by warning of an "inevitable" next pandemic known as "Disease X".